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Summary 
The Cytochrome P450 super-family is a fundamental requirement for the viability of 
most life, with Cytochrome P450 proteins having been identified in organisms ranging 
from bacteria to man. These enzymes may be subdivided into those that metabolise 
purely endogenous chemicals, and those that are involved in xenobiotic metabolism. Of 
the latter group it can be argued that CYP3A sub-family members rank as the most 
important; their high expression in the liver and wide substrate specificity mean that 
they are clinically important in the metabolism of many therapeutic drugs, and alteration 
in their activity is central to many clinically-relevant drug-drug interactions. 
In this review I will examine the human CYP3A enzymes, discussing their genome 
structure, common allelic variants and, in greatest detail, their transcriptional regulation. 
Through examination of these characteristics we will see both striking similarities and 
differences between the four human CYP3A enzymes, which may have important 
impacts on inter-individual response to chemical exposure. Finally, the role of nuclear 
receptors in regulating CYP3A gene expression, and indeed that of many other proteins 
involved in drug metabolism, will be examined: Such an examination will show the 
need to utilize a systems biology approach to understand fully how the human body 
responds to chemical exposure.  
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General Introduction 
Members of the cytochrome P450 (CYP) super-family of enzymes form an essential 
part of the body’s ability to carry out both anabolic and catabolic metabolism. Indeed, 
the very fact that members of this super-family have been identified in all studied 
organisms, from archaebacteria to humans, underlines their importance for organism 
survival [1]. Although all organisms possess CYP enzymes the number of CYP genes 
per organism is not constant, with more ancient organisms having fewer CYP genes. 
Indeed, it is the development of organisms with a gastro-intestinal tract that triggered a 
marked in CYP genes per organism, with increased chemical intake through the diet 
becoming a significant driver in the need to evolve new proteins capable of 
metabolising these chemicals [2]. Of the CYP isoforms present within an individual 
organism it is therefore possible to further subdivide them into those that mediate 
metabolism of endogenous chemicals and those that undertake xenobiotic metabolism, 
with members of this latter group being the focus of this review. Of the 57 CYP genes 
present in humans, is it really only member of families CYP1, CYP2 and CYP3 that are 
involved in xenobiotic metabolism. Of these, the CYP3A sub-family represents perhaps 
the most significant group due to two facts: First, CYP3A enzymes are the most 
abundant CYPs in human liver, comprising between 30-50 % of total CYP content, and 
hence represent the bulk of the CYP enzymes that a chemical is likely to be exposed to 
[3]. Second, a large active site results in substrate promiscuity, meaning that up 60 % of 
therapeutics in use today that are subject to metabolism are substrates for CYP3A sub-
family members [4]. Taken together it can be seen that for the majority of xenobiotics 
CYP3A plays some role in their metabolism in humans. 
 
Relevance of studying CYP3A gene expression 
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An amazing ability of the human body is its ability to handle xenobiotics, utilizing 
those that are beneficial to the body and removing rapidly those that might prove 
harmful. Indeed without such ability it is questionable whether Homo sapiens would 
have ever arisen, for the requirement of higher organisms to interact, and react, to their 
environment is an absolute. This metabolic capacity is not only large but flexible, with 
protein levels being increased in response to chemical exposure, resulting in the most 
efficient response to any xenobiotic. It is thus logical that to understand how the body 
responds to xenobiotics we must first understand how these chemicals interact with the 
metabolic network within the body. 
An important extension of this need to be able to understand the molecular 
mechanisms of body-xenobiotic interactions is the requirement to be able to predict 
such events, and in particular those that may result in toxicity. Prediction of toxicity as a 
result of the bio-activation of chemicals that occurs during metabolism is relatively 
straightforward, and can be achieved to a good degree of accuracy using in silico 
programs such as DERECK, TOPCAT or HazardExpert [5-7]. However and area of 
increasing concern are toxic reactions caused due to interactions between co-
administered chemicals. Combination chemotherapy is used increasingly in medial 
healthcare today, for the treatment of complex, life-threatening diseases such as HIV [8] 
or cancer [9], or in individuals with multiple, often long-term conditions, such as the 
elderly [10, 11] or during long-term prophylaxis of psychiatric disorders [12, 13]. Co-
administration of multiple drugs that are metabolised by the same enzyme system(s) to a 
single individual may potentially result in altered pharmacokinetics for some, none, or 
all of the co-administered compounds. If these effects occur to such an extent that 
clinical efficacy is lost, or toxicity produced, then such interactions are usually rapidly 
reported in the literature. Indeed, it has been estimated that adverse drug reactions are 
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the fourth largest killer in the Western World, and as such are a major health concern. 
Such drug-drug interactions may occur through two major mechanistic routes, inhibition 
of enzyme action or activation of gene transcription. Inhibition is a widely accepted 
problem, and much research has been undertaken in this area; the interested reader is 
directed to these recent reviews [14-16]. The focus of this review will be on the increase 
in protein number caused by activation of gene transcription. It should be noted that 
increased protein expression can also occur by chemical-mediated increases in transcript 
(e.g. clotrimazole [17] or protein (e.g. triacetyloleandomycin [18]) stability, but these 
are more the exception rather than the rule and will not be discussed herein. 
The presence of a wide-substrate binding profile for an enzyme is a direct correlate 
with predilection for drug-drug interactions and hence it is not surprising that CYP3A 
enzymes are subject to large number of such interactions. Table 1 presents a selection of 
established drug-drug interactions involving activation of CYP3A gene transcription. 
An interesting point to note is that several of these are not ‘drug’-‘drug’ interactions in 
the true sense as the inducing agent is not a therapeutic agent; this underlines the 
importance in understanding the molecular mechanisms of drug-drug interactions as 
individuals may be exposed to many of the combinations without their physicians, or 
indeed their own, knowledge.  
 
[TABLE 1 ABOUT HERE] 
 
CYP3A family members 
Despite its high biological significance with regards to xenobiotic metabolism, the 
CYP3A sub-family is relatively compact, comprising only four members in humans: 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 [19]. Following the basic definition of 
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sub-family membership, the sequences for these proteins demonstrate at least 70 % 
identity, with the exact matches being given in Table 2. 
 
[TABLE 2 ABOUT HERE] 
 
A particular feature of CYP-biology in general, and one that is particularly relevant 
to the CYP3A sub-family in particular is that large inter-individual variations in enzyme 
expression have been reported [20-23]. Such variation is probably due to a combination 
of chemical-mediated induction/inhibition of CYP activity (e.g. environment) and the 
presence of activity/expression polymorphisms (e.g. genetic). The exact input of these 
two factors is a matter of debate, with estimates for the genetic contribution towards the 
variation in CYP3A expression ranging from 60 % to 90 % [24].  A large compendium 
of CYP alleles is held by the official allele nomenclature committee 
(http://www.imm.ki.se/CYPalleles/), which currently lists 40 variants for CYP3A4, 24 
for CYP3A5, 7 for CY3A7 and 5 for CYP3A43. However a survey of the literature 
reveals the majority of these variants are either of little biological significance or low 
frequency, and hence would not act as a major contributor to the observed inter-
individual variability in CYP3A activity [22, 25-29]: Selected variants with the largest 
potential biological impact are discussed in detail within the relevant sections below. 
This lack of ‘major’ allelic variants to account for inter-individual variation, as for 
example seen in CYP2D6 [26], suggests that inter-individual variation in CYP3A 
activity is the result of one of three scenarios. First that the large number of ‘minor’ 
variants combine together to produce the total variation in CYP3A activity that is 
observed in the population. Second that environmental impact is the major player in 
determining CYP3A activity, and individual exposure to CYP3A inhibitors/inducers 
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determines CYP3A activity. Third, that genetic variation exists outside the CYP3A 
genes, which impacts upon their expression. Of these possibilities, the first seems 
unlikely as the frequency of these variants in combination still appears too low to 
explain all the observed variation in activity, as will be discussed below. However, the 
second and third possibilities are equally valid, and I suspect that the true answer is a 
combination of both; the exact ratio of these inputs being as yet undetermined. 
Whereas inter individual variation in CYP3A activity is generally accepted, 
investigations for potential sex differences in expression are much more equivocal. In 
two separate studies erythromycin N-demethlyation has been reported to be greater in 
females, by 24 % [30] and 36 % [31], suggesting that a slight sex difference may exist. 
However, the difficulty in removing confounding factors from such studies means that 
such data must be treated with caution. 
When studying the CYP3A sub-family it is perhaps fair to say that equal importance 
should not be given to all family members. Although all individuals tested to date 
appear to express CYP3A activity [19], the different isoforms input differently into this 
activity: Each isoform will be discussed below in more detail, along with the major 
polymorphisms associated with the corresponding gene.  
CYP3A4 
CYP3A4 transcripts are undetectable in foetal liver [32], but rapidly rise after birth 
whereupon CYP3A4 becomes the predominant liver CYP in the majority of adult livers 
[4, 33]: Due to this fact CYP3A4 is the best studied of the CYP3A sub-family members 
in humans.  
The wide substrate binding profile and catalytic activity of CYP3A4 results in a 
number of possible biotransformation reactions, encompassing C- and N-oxidations, N- 
and O-dealkylations, nitro reductions and dehydration reactions [19]. Recent 
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crystallographic study of CYP3A4 [34], combined with homology modelling [35-37] 
and mutagenesis of recombinant CYP3A4 [38-43] has identified key residues within the 
active site that are responsible for reaction catalysis. 
A number of CYP3A4 allelic variants have so far been identified that may 
contribute to the known inter-individual expression of CYP3A [27, 28, 44-47]. Of these, 
some variants have been shown to result in the total ablation of holoenzyme production 
(e.g. R130Q and P146L [45]), whereas others impact directly on enzyme activity (e.g. 
L373F [45]and  F189S [46]). However, the relatively low frequency of these alleles 
means that the overall input of individual variants towards the observed variation in 
CYP3A activity is questionable [48]. For example, one of the more widely expressed 
variants is F189S, yet this variant only has an allelic frequency of 2 % in Caucasians 
[46]. Recently, Eiselt and colleagues identified eight CYP3A4 variants, of which only 
four have a substantial effect of CYP3A4 activity. The combined heterozygote 
frequency of these eight variants was only 7.5 % in the European population [45], 
underlying the disparity between the impact of the identified CYP3A4 variants on 
CYP3A activity and the much larger total variation in CYP3A activity observed in the 
general population. 
CYP3A5 
In parallel with CYP3A4, significant expression of CYP3A5 is not associated with 
the developing foetus, with low level expression being detected in less than 10 % of 
human foetal livers [49]. However, in contrast to CYP3A4, which is expressed in all 
adult human livers, CYP3A5 expression appears to be limited to approximately one-
quarter of individuals [49]: In these individuals, however, the level of CYP3A5 is often 
equal to, or exceeds, that of CYP3A4, making it a significant player in determining 
overall CYP3A activity for these individuals [50]. Given the known differences in 
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metabolic capacity between CYP3A isoforms [51-55], such variation in expression may 
have a potentially large impact on the wide inter-individual variation in CYP3A activity 
observed in the liver [4]. It is also worthy of note that CYP3A5 is expressed in several 
organs in which CYP3A4 is not highly expressed, for example skeletal muscle [56], and 
hence differences in metabolic profile between liver and these organs may exist.   
The very fact that CYP3A5 is expressed in only approximately one-quarter of adult 
livers suggests the presence of allelic variants for this gene. As stated earlier, the 
majority of identified SNPs for CYP3A5 are of little population significance, due either 
to their low frequency or small biological impact [29]. However, Kuehl and colleagues 
identified a family of allelic variants for which both a significant population and 
biological effect exists. They identified three splice acceptor site polymorphisms that 
resulted in the potential inclusion of mini-exons between exons 3-4, 4-5 and 5-6 
(designated exons 3B, 4B and 5B) [57]. Inclusion of these mini-exons introduces a stop 
codon in the CYP3A5 transcript, thus producing a truncated, non-functional CYP3A5 
protein [57]. A solid hypothesis would therefore be that the variants including these 
mini-exons (CYP3A5*3 SV1, 2 and 3) are actually held by the majority of individuals 
and result in low/negligible CYP3A5 expression, with the minority expressing the wild 
type, fully functional, variant.  Subsequent screening of diverse ethnic groups has 
suggested that this allelic variant (CYP3A5*3) may represent a good marker for overall 
CYP3A activity, and although it does not account for all non-expression of CYP3A5 
may be of some use in prospective screening [58-60]. 
CYP3A7 
Whereas CYP3A4/5 are the predominant CYP3A isoforms in adult liver, in the 
developing foetus CYP3A7 is the predominant CYP3A expressed, and in an inverse 
relationship to CYP3A4/5, levels of CYP3A7 decrease rapidly at birth [32, 33, 61, 62]. 
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Approximately one-half of adults have detectable levels of CYP3A7 within the liver, 
although in general this is at lower levels to both CYP3A4 and CYP3A5 and probably 
has a negligible input into CYP3A-mediated metabolism [32]. However, approximately 
10 % of adults do have significant levels of CYP3A7; this increased expression being 
associated with the CYP3A7*1c allele, which affects the PXR response element in the 
CYP3A7 promoter. In these individuals CYP3A7 may contribute up to one third of the 
CYP3A content of the adult liver [63], and thus have a significant input into CYP3A-
mediated metabolism. Liver is not the only organ that shows significant adult 
expression of CYP3A7, with an increase in endometrium and placental expression of 
CYP3A7 being observed in pregnant women [64] and during the secretory phase of the 
menstrual cycle [32]. It has been proposed that the increased CYP3A7 expression 
during pregnancy may be foeto-protective, reducing 6β- and 16α-hydroxylation of 
steroid precursors, which if unchecked could result in dysregulation of steroid levels in 
the developing foetus [65]. 
CYP3A43 
In 2001 a new member of the human CYP3A sub-family was cloned, termed 
CYP3A43 [66-68]. CYP3A43 appears to be expressed in a similar range of tissues to 
other members of the CYP3A subfamily (e.g. liver, kidney, pancreas, testes and 
prostate) and has been identified in both adult and foetal samples. However, the 
expression of this isoform appears to be at very low levels in comparison to 
CYP3A4/5/7, with adult hepatic expression being only approximately 0.1 % and 2 % of 
mean CYP3A4 and CYP3A5 transcript levels respectively [67]. In addition, studies on 
the metabolic capability of CYP3A43 demonstrate very low 6β-hydroxylation activity 
towards testosterone, suggesting a weakly metabolically active isoform. This poor 
metabolic activity has been attributed to six amino acid substitutions in the active site of 
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the enzyme compared to CYP3A4 [66]. The total identity of CYP3A43 to other 
members of the CYP3A sub-family is low, on average 73 % (Table 1), just qualifying it 
as a member of this sub-family.  This combination of low identity, low level expression 
and low activity means that he biological significance of CYP3A43 with regards to total 
human CYP3A activity is probably negligible. 
 
CYP3A gene structure 
Examination of the genomes of divergent organisms such as plants and fungi has 
revealed that many of the CYP genes are present in clusters on chromosomes [69, 70]. 
Such clustering presents strong evidence that they originated via gene duplication 
events [70], either as discrete events or as part of whole genome duplications [71, 72]. 
The CYP3A sub-family of genes is no exception of this rule, and exist as a cluster on 
human chromosome 7q21-q22.1 [73, 74]. The CYP3A4, CYP3A7 and CYP3A5 genes lie 
in a head-to-tail configuration in the order listed, with CYP3A43 located in the reverse 
orientation, 44.8 Kb away from CYP3A4. Two non-processed pseudogenes exist 
(CYP3A5P1 and CYP3A5P2) in the regions between CYP3A5 – CYP3A7 and 
CYP3A4-CYP3A7 respectively, also in head-to-tail orientation [73]. Finta and 
Zaphiropoulos reported a CYP3A7 derived transcript that contained exons from the 
CYP3A5P1 pseudogene, suggesting evolution within the CYP3A gene cluster may 
occur through the capture of downstream exons in addition to complete gene 
duplication events [73].  
In general, the basic structure of the CYP3A genes is the same for each member, 
comprising of 13 exons with a processed transcript size of approximately 2 Kb (Table 
3).  
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[TABLE 3 ABOUT HERE] 
 
As can be seen from table 3, each human CYP3A gene has relatively short 5’ 
untranslated regions, with a mean 5’ UTR length of 101nt, considerably below the 
average 5’ UTR length for human transcripts of 150nt [75]. Interestingly, the 3’ UTR 
lengths for human CYP3A genes is quite variable, ranging from 111nt in CYP3A5 to 
1152nt in CYP3A4, compared to the human mean 3’ UTR length of approximately 
500nt [75]. The molecular rationale behind these differences in 3’ UTR length is 
currently unknown, but as UTRs commonly contain regulatory regions that effect 
transcript stability or translation efficiency it is possible that these differences are 
important in the functionality of the CYP3A transcripts and their ability to produce 
CYP3A protein. In silico analysis of the 3’ UTR regions of the human CYP3A genes 
using the miRanda algorithm (http://microrna.sanger.ac.uk/index.shtml) reveals a 
number of putative micro-RNA binding sites that may underlie the molecular 
functionality of CYP3A 3’ UTRs [76, 77]. It should be noted that such prediction does 
not denote function, with no empirical evidence for any of these sites having yet been 
demonstrated. However, the conservation of sites across evolutionary time is a good 
predictor of biological significance, and several of these sites are conserved between 
humans and chimpanzee’s (5.5M years divergence [72]), with some even conserved 
between humans and mice (40M years divergence [72]); the total number of predicted 
microRNA sites, with details on those conserved between species are presented in table 
4. The area of microRNA regulation of gene expression is a rapidly expanding area, and 
as shown above has exciting potential implications for the expression of CYP genes. 
 
[TABLE 4 ABOUT HERE] 
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Common regulatory elements for CYP3A sub-family members 
A large number of studies have now been undertaken to examine the molecular 
mechanisms underlying xenobiotic-mediated activation of CYP3A gene expression. 
Whereas the majority of this work has focussed on CYP3A4 as it encodes the major 
CYP3A protein in the majority of adult human livers, sufficient work has been 
undertaken on the regulatory elements of CYP3A5 and CYP3A7 that a comparison is 
worthwhile; indeed, by studying common elements we may learn more about the 
general mechanism through which the body responds to chemical exposure. Little or no 
work has been undertaken on the CYP3A43 regulatory regions and, as stated 
previously, the biological significance of this isoform is limited: CYP3A43 will 
therefore not be examined further in this section. 
CYP3A regulatory region overview and general transcription factors binding 
The proximal promoter regions of CYP3A4, CYP3A5 and CYP3A7 share a high 
degree of identity. Over the first 1Kb upstream from the transcription start site CYP3A4 
and CYP3A7 exhibit a remarkable degree of identity, 91 % [78]. Indeed, this region of 
identity extends beyond the proximal promoter to the upstream xenobiotic-response 
enhancer module (XREM; -7836 bp to -7607 bp), with identify over this region being 
90 % [79, 80]: After this point the sequences diverge sharply, with identity dropping to 
approximately 25 %. Such a high degree of similarity is highly suggestive that modes of 
regulation for these two genes are shared, as indeed there is much evidence to suggest 
this is the case [79, 81].  
By comparison the first 1.5 Kb of the CYP3A5 proximal promoter shares only 60 % 
and 59 % identity with the corresponding CYP3A4 and CYP3A7 regulatory regions 
[68, 82]. The region first identified by Jounaidi and colleagues as the CYP3A5 proximal 
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promoter is in fact the promoter of the unprocessed pseudogene CYP3A5P1 [68, 83]; 
however as these two regions share over 90 % identity the conclusions drawn by 
Jounaidi and colleagues are still valid for the correctly identified CYP3A5 proximal 
promoter. Closer examination of the CYP3A5 proximal promoter identifies a breakpoint 
at approximately 700 bp upstream of the transcription start site past which identity with 
CYP3A4 and CYP3A7 promoter sequences drops rapidly [68]. This is suggestive that a 
gene modification event has occurred at some point in evolution, such as a large 
deletion/insertion or gene conversion with a non-CYP3A gene, resulting in this 
dramatic cut-off in sequence identity. 
A second difference between CYP3A5 and CYP3A4/7 is that whereas both 
CYP3A4 and CYP3A7 proximal promoters contain a classical TATAA-box and basic 
transcription element (BTE) [78, 80], the CYP3A5 proximal promoter has a modified 
TATAA-box (CATAA) and BTE [83], which is often associated with lower 
selectivity/multiple positions for the transcription start site. Work by Iwano 
demonstrated that both Sp1 and Sp3 were able to bind to the BTE (-66 bp to -45 bp) of 
CYP3A5, confirming their unpublished work suggest that Sp family members could 
bind to the BTE of CYP3A4 and CYP3A7 [83].  
Auxiliary transcription factors  
Examination of the proximal promoters for CYP3A4, CYP3A5 and CYP3A7 reveals 
a number of conserved transcription factor binding sites. Before describing these sites in 
detail it should be noted that the literature in this area is somewhat confusing and should 
be taken with a degree of caution due to the mixture of techniques used to identify these 
sites. Many papers quote in silico identification of binding sites, with no empirical 
evidence for functionality, whereas others have used a host of molecular techniques to 
show functionality: The reader is thus warned to treat each assignment with caution 
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until the experimental data is presented to confirm a putative binding site assignment. 
Figure 1 shows the suggested transcription factor binding sites for the CYP3A4/5 and 7 
regulatory regions, discriminating between those for which only an in silico annotation 
exists, and those for which empirical binding data has been shown. 
Initial in silico examination of the CYP3A4 proximal promoter revealed putative 
transcription factor binding sites for Octamer binding protein (Oct1), CCAAT-binding 
protein (CP1), activator protein 3 (AP3), and the liver-enriched transcription factors 
HNF-4 and 5 [78]. Deletion construct analysis of the CYP3A4 proximal promoter (-
1240 bp to +11 bp) by Ourlin and colleagues demonstrated the effect of C/EBPα and 
DBP on the CYP3A4 proximal promoter, although exact interaction sites were not 
identified [84]. Subsequent DNase I footprinting analysis of the initial 250 bp of the 
CYP3A4 proximal promoter has confirmed protein:DNA interactions within several of 
in silico predicted regions, as well as adding putative binding sites for sites for 
specificity protein 1 (Sp1) and activator protein 2 (AP2) [85]. Site-directed mutagenesis 
has been used to confirm functionality for a few sites within the CYP3A4 proximal 
promoter; Sp1 (-104 bp to -97 bp [85]), C/EBPα (-132 bp to -121 bp [85, 86]) and 
HNF3 (-195 bp to -186 bp [85]). Ablation of these sites resulted in either decreased 
basal expression (C/EBPα and HNF3), or reductions in drug-mediated activation of 
CYP3A4 expression (C/EBPα, HNF3 and SP1). The involvement of another liver-
enriched transcription factor (HNF4α) in regulation of CYP3A4 gene expression was 
demonstrated by Tirona and colleagues, who used conditional transgenic mice to show 
that this factor was import for both basal and drug-mediated induction of CYP3A4 [87]. 
Further examination of the regulatory regions of CYP3A4 revealed that this control was 
through direct binding to HNF4 binding elements located within the XREM located -
7785 bp to -7772 bp relative to the transcription start site [87]. In 2004, Matsumura and 
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colleagues identified a second enhancer module for CYP3A4, the constitutive liver 
enhancer module (CLEM4) [88]. The location of this unit (-11.4 Kb to -10.9 Kb) is 
within a region of poor sequence conservation between members of the CYP3A gene 
family, and hence the CLEM4 unit appears to be specific for CYP3A4. Supershift 
analysis over this region identified binding sites for HNF1α, HNF4α, USF1 and AP1, 
all of which were required for maximal enhancer activity. Such a finding is at odds to 
the work of Tirona who demonstrated that in transgenic mice HNF1 played no role in 
CYP3A gene expression [87]; at present it is not clear if this difference is due to 
species-specific regulation or compensation for loss of HNF1 by other factors in the 
knock-out animals. 
Due to the high sequence identity between the proximal promoters of CYP3A4 and 
CYP3A7 it is logical to presume shared mechanisms of regulation, and therefore 
transcription factor binding sites. Several studies have produced evidence to support 
such an hypothesis [79, 81, 89, 90], although it should be noted that such data is not 
unequivocal, with some differences in regulation between CYP3A4 and CYP3A7 being 
noted [91]. Little experimental work has been done to characterise the molecular 
mechanisms underlying CYP3A7 regulation, and hence although conserved 
transcription factor binding sites can be observed between CYP3A4 and CYP3A7 
proximal promoter (see Figure 1) such comparisons must be treated with caution. Work 
by Ourlin and colleagues has confirmed the action of C/EBPα on the CYP3A7 proximal 
promoter, mirroring the interaction between this factor and the CYP3A4 proximal 
promoter, but the exact interaction site was not determined [84]. 
As noted previously, CYP3A7 is predominantly expressed in the developing foetus, 
whereas CYP3A4 is adult-specific; considering the high identity between the regulatory 
regions of these genes a valid question is what underlies this difference in temporal 
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expression? The previously described CLEM4 enhancer unit of CYP3A4 does not exist 
in the corresponding genomic location upstream of the CYP3A5/7/43 genes. As the 
CLEM4 unit appears to have implications for basal expression, as opposed to drug-
activated expression, then it is possible that this unit may play a role in CYP3A4-
specific expression in humans [88].In addition, work by Saito and colleagues identified 
an NF-ΚB-like element within the CYP3A7 promoter (-2326 bp to -2297 bp) that is 
ablated by a single base-pair change in the CYP3A4 promoter [92]. This NF-ΚB-like 
element was shown to bind Sp1 and Sp3, two factors that are often associated with the 
basal regulation of gene expression [93]. The activity of this NF-ΚB-like element was 
also shown to be modulated indirectly through the action of HNF3 and upstream 
stimulatory factor 1 [92]. In addition,  
In silico analysis of the CYP3A5 gene regulatory regions has revealed a number of 
putative binding sites in common with CYP3A4 and CYP3A7 (Figure 1). In addition, 
Iwano and colleagues have demonstrated that the predicted inverted CCAAT-box (-75 
bp to -71 bp) was functional [83]. CCAAT-boxes are capable of interacting with a 
number of auxiliary transcription factors, including NF-Y, NF-1 and C/EBP family 
members and are important in basal gene expression. Iwano and colleagues 
demonstrated that NF-Y had the highest affinity for the CYP3A5 CCAAT-box, and that 
this element showed co-operative binding with the BTE-associated Sp family members 
Ligand-activated transcription factors  
Ligand-activated transcription factors are central to the ability of genes encoding 
proteins involved in ADME to respond to chemical exposure. These transcription 
factors act as xenosensors and, once activated by the presence of ligand, cause an 
increase in the expression of a target gene set responsible for the efficient processing of 
the stimulating xenobiotic [94]. The largest family of ligand-activated transcription 
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factors implicated in regulating drug metabolism are the nuclear receptors, a super-
family of 48 proteins in man [95]. Amongst these proteins are several liver enriched 
transcription factors such as the HNFs, whose role in regulating CYP3A gene 
expression has been covered in the previous section. However, in terms of controlling 
and co-ordinating the response to xenobiotics then the most important factor, with 
respect to CYP3A genes, is the pregnane-X receptor (PXR; NR1I2). PXR was first 
identified in mouse by Kliewer and colleagues [96], through scanning of a mouse liver 
cDNA library for sequences similar to the ligand-binding domain of known nuclear 
receptors. Ablation of PXR expression in transgenic mice results in reduced basal 
expression of CYP3A11, the murine orthologue of CYP3A4, and the complete loss of 
pregnenalone-16α-carbonitrile (PCN)-mediated activation of CYP3A11 expression 
[97].  
PXR has now been identified in several other species including representatives from 
the rodentia (mouse [96] and rat [98]), lagormopha (rabbit [99]), carnivora (dog, 
predicted), bovidae (cow, predicted) and primates (macaque [100] and chimpanzee, 
predicted). Simultaneous identification of human PXR by three groups has led to some 
confused nomenclature, with PXR, PAR and SXR being used interchangeably [101-
103]: PXR will be used throughout herein for clarity.  Examination of the chicken 
genome revealed a nuclear receptor (chicken xenobiotic receptor, CXR) with sequence 
identity similar to both PXR (mean 40 % identity with rat, mouse and human PXR) and 
another, closely related nuclear receptor the constitutive androstane receptor (CAR; 
NR1I3) (mean 40 % identity with rat, mouse and human CAR) [104]. As no orthologue 
for PXR or CAR exists in chicken it has hence been postulated that CXR represents an 
evolutionary antecedent [105, 106], thus putting the divergence of the PXR and CAR 
genes at after the divergence between aves and mammalian some 310 million years ago 
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[72]. A deposited sequence for zebrafish PXR exists within GenBank, which would 
argue against such a timescale of divergence. However, analysis of this sequence 
suggests that while it is more closely related to PXR (mean 40 % identity with rat, 
mouse and human PXR) than CAR (mean 30 % identity with rat, mouse and human 
CAR), resulting in its designation as zebrafish PXR, it is shares 40 % identity with 
CXR. The latter observation would therefore be consistent with CXR, and indeed 
zebrafish PXR, representing antecedents of the PXR/CAR xenosensing receptors in 
mammals.  
PXR binds to DNA as a heterodimer with RXRα [107], and may utilize response 
elements consisting of two half sites of AGGTCA, arranged as either an everted repeat 
separated by six nucleotides (ER6), or a direct repeat separated by three (DR3) or four 
(DR4) nucleotides. The exact choice/binding efficiency at these elements appear to be 
dependant upon both the species [101, 108, 109] and the genomic context of the 
element [110]. Examination of the regulatory sequences of CYP3A4 reveals an ER6-
type PXR binding site (PXRE) present at -169 bp to 152 bp [101-103], and ablation of 
this site reduces xenobiotic-mediated activation of CYP3A4 gene expression [111]. In 
addition to this PXRE within the proximal promoter of CYP3A4, work by Goodwin and 
colleagues identified two distal ER6-type PXREs (-7738 bp to -7717 bp) and (-7698 bp 
to -7682 bp) within the XREM [112]: Indeed, in vivo reporter gene assays suggest that 
this element is of more import in determining CYP3A4 gene expression, and the 
activation of its transcription by xenobiotics [113]. 
Given the sequence conservation between CYP3A4 and CYP3A7 regulatory regions 
it is perhaps not surprising that a functional ER6-type PXRE is present in the proximal 
promoter of CYP3A7 [81], and this gene also utilizes an XREM containing ER6-type 
PXREs [79]. Regulation of CYP3A5 gene expression by PXR has been more equivocal 
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with initial reports showing little activation of CYP3A5 expression by prototypical PXR 
ligands [114, 115]. However, a recent report has confirmed the functionality of the ER6-
type PXRE within the proximal promoter of CYP3A5 [116] that was first suggested by 
Iwano and colleagues [83]. Thus, the regulation of drug-mediated activation of CYP3A 
gene transcription by PXR has now been demonstrated to be conserved through the 
three major human CYP3As. Crucially, the distal XREM appears to be absent from the 
CYP3A5 gene; as this is necessary for maximal activation of CYP3A4 and CYP3A7 
gene expression in response to xenobiotics this may explain why PXR-mediated 
activation of CYP3A5 gene expression has been controversial [68]. 
In addition to PXR binding to the promoters/enhancers of human CYP3A genes it 
should be noted that promiscuity in response element specificity exists, with several 
other nuclear receptors capable of binding to ER6, DR3 and DR4 elements. Of 
particular note is the previously mentioned CAR. The interested reader is referred to the 
following reviews that extensively cover the interplay between PXR and CAR and their 
co-ordinate regulation of CYP3A genes [117-121]. The implications of this promiscuity 
are twofold. First, that biological redundancy exists within the xenosensing systems 
within the body, acting as a ‘metabolic safety net’ to ensure the most efficient response 
to any chemical stimulus [122]. Second, this potential cross-talk results in an interaction 
network, whereby the relative expression of receptors and/or affinity of ligand/response 
element determines the gene set activated by a specific chemical [123]. This interaction 
network would thus be capable of fine tuning the response to any particular stimulus far 
above what could be achieved with a series on non-interacting nuclear receptors. Indeed 
recent evidence suggests that nuclear receptors regulate the expression of each other, 
further increasing the complexity of such interaction networks [124-127]. The sum total 
of this interaction network may well go some way to explain the observed inter-
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individual variation in CYP3A activity, with a host of minor changes (both 
environmental and genetic) to different factors within the network combining to 
produce the variable expression in CYP3A genes. 
Conclusion 
The genetic regulation of the cytochrome P450 genes is nearing completion with 
respect to characterisation. The completion of many genome sequencing projects, 
particularly that of four higher mammals, along with the number of at, or nearing draft 
status means that the coding of the regulatory regions for mammalian CYP genes is now 
known. In silico analysis has allowed the prediction of control mechanisms from this 
known coding sequence, and finally molecular analysis have allowed the functionality 
of these predicted mechanisms to be examined. Having characterised the functional 
interactions occurring within the CYP regulatory regions we are now left with perhaps 
the greatest challenge, understanding how all these factors interact together to produce 
the ultimate expression of CYPs (and indeed other proteins involved in drug 
metabolism), and the regulation of this expression in response to stimulus. The 
interactions of nuclear receptors are a good example of such an interaction network, and 
it is perhaps through the continued study of these ligand-activated transcription factors 
that we will begin to understand more about how the interactome actually works. Thus 
we are entering an exciting period of discovery in drug metabolism, where work will 
evolve from the study of the individual to the study of the system. It is this ‘systems 
biology’ that will yield the ultimate benefits from the rigorous characterisation work 
currently being completed; the ability to model and predict human biological responses 
to chemical stimulus. 
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Table 1: Examples of CYP3A-mediated drug-drug interactions elicited through 
induction 
Inducing Chemical Victim Drug Clincial Effect Reference 
Phenytoin Felbamate ⇑  Clearance [128] 
St Johns Wort Indinavir ⇓AUC, ⇓Cmax [129] 
St Johns Wort Cyclosporin ⇓ Plasma levels [129] 
Rifampicin Cyclosporin ⇓ Plasma levels [130] 
Rifampicin Quinidine ⇑ Clearance [131] 
Rifampicin Efavirenz ⇓ AUC [132] 
Troglitazone Terfenadine ⇓ Plasma levels [133] 
Troglitazone Paracetamol ⇑ Formation of NAPQI [134] 
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Table 2: Amino acid identity in the CYP3A sub-family 
 
 CYP3A5 CYP3A7 CYP3A43 
CYP3A4 84% 88% 75% 
CYP3A5  81% 75% 
CYP3A7   70% 
 
Amino acid sequences for CYP3A4 (NP_059488, 503aa), CYP3A5 (NP_000768, 
502aa), CYP3A7 (NP_000756, 503aa) and CYP3A43 (NP_073731, 504aa) were 
aligned using DiAlign (http://www.genomatix.de/) and sequence identity calculated.
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Table 3: Human CYP3A Gene Structure 
 CYP3A4 CYP3A5 CYP3A7 CYP3A43 
Number of 
Exons 
13 13 13 13 
Ref transcript  
and length 
NM_017460 
2768nt 
NM_000777 
1707nt 
NM_000765 
2080nt 
NM_022820 
2167nt 
5’ non-coding 
exon? 
No No No No 
5’ UTR length 105nt 88nt 106nt 104nt 
3’ UTR length 1152nt 111nt 463nt 549t 
 
UTR = untranslated region 
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Table 4: Predicted microRNA binding sites in human CYP3A 3’ UTRs 
Gene Transcript 
3’UTR 
length 
Predicted 
miRNA  sites 
Number of miRNAs 
that can bind to 
these sites 
Conserved 
sites 
Conserved 
miRNA 
Position of 
conserved 
site  
Conserved species 
CYP3A4 ENST00000336411 1152nt 7 7 3 hsamiR330 3-25 Hs + Pt 
 
     hsamiR152 128-151 Hs + Pt  
 
     hsamiR361 281-303 Hs, Pt + Mm 
 
     dremiR27e 593-614 Hs + Pt 
CYP3A5 ENST00000222982 111nt 2 4 2 hsamiR520g 2-25 Hs + Pt 
 
     dremiR216b 41-62 Hs + Pt 
CYP3A7 ENST00000336374 463nt 7 10 1 miR27b  Hs, Pt + Mm 
CYP3A43 ENST00000222382 549nt 4 6 2 hsamiR488 53-75 Hs + Pt 
      mmumiR350 149-168 Hs + Pt 
Data derived from http://microrna.sanger.ac.uk/index.shtml and http://www.microrna.org/ and shows the total number of predicted miRNA 
binding sites per UTR, the microRNAs that can bind to these sites, plus details of micoRNA binding sties conserved across species . Hs = Homo 
sapiens, Pt = Pan troglodytes and Mm = Mus musculus
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Figure Legends 
 
Figure 1: Known and putative transcription factor binding sites within the 
regulatory regions of human CYP3A genes. The major identified regulatory regions 
for CYP3A4/5 and 7 are presented, along with putative transcription factor binding 
sites. Where such sites have been shown to be functional through molecular analysis the 
site is labelled in bold to denote this. For sites where multiple transcription factors may 
bind factors that have been shown to interact with this site are included in parentheses. 
Data from [78-80, 82-85, 87, 88, 90, 92, 112, 135] 
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